Phase I study evaluating the Fc-optimized FLT3 antibody FLYSYN in AML patients with measurable residual disease - Heitmann, Jonas S.; Schlenk, Richard Friedrich; Dörfel, Daniela; Kayser, Sabine; Döhner, Konstanze; Heuser, Michael; Thol, Felicitas; Kapp-Schwoerer, Silke; Labrenz, Jannik; Edelmann, Dominic; Märklin, Melanie; Vogel, Wichard; et al. (Journal of hematology & oncology, 2023)
Gesehen am 02.04.2024